Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$32.67
−$0.24 · -0.73%
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Regular session
$32.67
−$0.24 · -0.73%
Regular session · ET · Market data may be delayed.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Day range
Current $32.67
52-week range
Current $32.67
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
53
Fair Value
Sentiment
70
Bullish
Risk
66
High Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Day range
Current $32.67
52-week range
Current $32.67
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 344.23M USD | 332.07M USD | 219.79M USD | 137.04M USD | 94.09M USD |
| Cost of goods sold | 71.03M USD | 60.21M USD | 44.98M USD | 32.01M USD | 15.82M USD |
| Gross profit | 273.2M USD | 271.86M USD | 174.81M USD | 105.03M USD | 78.26M USD |
| Research and development | 51.85M USD | 52.04M USD | 53.62M USD | 44.9M USD | 29.65M USD |
| Selling, general, and administrative | 229.32M USD | 200.05M USD | 180.15M USD | 143M USD | 86.74M USD |
| Operating expenses | 316.01M USD | 263.19M USD | 242.78M USD | 177.89M USD | 118.34M USD |
| Interest income | 11.77M USD | 12.92M USD | 10.62M USD | 3.97M USD | 68K USD |
| Interest expense | 86K USD | 577K USD | 11K USD | 17K USD | 1K USD |
| Depreciation and amortization | 40.77M USD | 16M USD | 12.33M USD | 10.54M USD | 3.41M USD |
| Operating income | −42.81M USD | 8.67M USD | −67.98M USD | −72.86M USD | −40.08M USD |
| Net income | −24.16M USD | 18.25M USD | −57.47M USD | −67.14M USD | −31.29M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$39.00
19.38% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM25.12M0.03%80.51B USD0.19%$295.44-0.19%
Vanguard Morningstar Total Stock Market ETFVTI23.88M0.00%2.3T USD0.03%$378.22-0.40%
Vanguard Extended Market ETFVXF9.74M0.01%93.7B USD0.05%$242.2-0.19%
iShares Russell 2000 Value ETFIWN9.16M0.06%14.61B USD0.24%$223.33-0.57%
iShares Biotechnology ETFIBB7.23M0.07%10.73B USD0.44%$208.18-1.76%
EA Bridgeway Omni Small-Cap Value ETFBSVO4.8M0.19%1.71B USD0.47%$29.645-0.79%
Schwab U.S. Small-Cap ETFSCHA4.71M0.02%22.93B USD0.03%$34.635+0.25%
Vanguard Russell 2000 ETFVTWO4.71M0.03%17.4B USD0.06%$119.44-0.15%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBEA Bridgeway Omni Small-Cap Value ETFBSVOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
